Develops drugs for cardiovascular and neuromuscular diseases.
Jun 2026Revenue $67.7M/yrExpenses $776M/yr
Fell below break-even Feb 2017Cash runway ≈ 2.0 years from Jun 2026
Figures by year
When will Cytokinetics be profitable again?
Its expenses passed its revenue in Feb 2017. In the 12 months to Jun 2026, revenue was $67.7M and expenses $776M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $88.0M | $700M | −$612M |
| Dec 2024 | $18.5M | $555M | −$536M |
| Dec 2023 | $7.53M | $504M | −$496M |
| Dec 2022 | $94.6M | $419M | −$324M |
| Dec 2021 | $70.4M | $257M | −$186M |
| Dec 2020 | $55.8M | $150M | −$93.9M |
| Dec 2019 | $26.9M | $126M | −$98.9M |
| Dec 2018 | $31.5M | $120M | −$88.9M |
| Dec 2017 | $13.4M | $127M | −$113M |
| Dec 2016 | $106M | $87.7M | $18.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.